Posted by Michael Wonder on 17 Feb 2026
US FDA accepts Bristol Myers Squibb's new drug application for iberdomide in patients with relapsed or refractory multiple myeloma
17 February 2026 - Bristol Myers Squibb today announced that the US FDA has accepted a new drug application for iberdomide combined with standard treatment (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma.
Iberdomide is part of an investigational, new class of medicines called cereblon E3 ligase modulator (CELMoD) agents.
The FDA has granted a PDUFA date of 17 August 2026 for this indication.
